Tess Cameron
Directeur Financier/CFO chez RESEARCH ALLIANCE CORP. II
Profil
Tess Cameron is a Principal, Strategic Finance at RA Capital Management.
Tess’s primary responsibility is to partner with our portfolio companies as a strategic finance advisor.
Tess comes to RA from Foghorn Therapeutics, where she was Head of Finance.
Prior to Foghorn, Tess held finance leadership roles at Wave Life Sciences, where she was responsible for FP&A and corporate finance, and Biogen, where she was the finance lead for the CMO and the neurodegeneration portfolio.
Prior to joining biotech/pharma, she was a specialist in the corporate finance team at McKinsey &Co, focused on corporate transactions.
Tess has a BA with a double major in Economics and Peace & Conflict studies from the University of Toronto, Canada.
Postes actifs de Tess Cameron
| Sociétés | Poste | Début |
|---|---|---|
| RESEARCH ALLIANCE CORP. II | Directeur Financier/CFO | 17/07/2020 |
RA Capital Management LP (Private Equity)
 RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Corporate Officer/Principal | 01/06/2020 |
Avilar Therapeutics, Inc.
 Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avilar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of extracellular protein degraders. The company is based in an undisclosed location. The company has developed a proprietary discovery platform that includes novel, high-affinity, small molecule asgpr ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of atac mediated endocytosis and degradation. Avilar is developing atacs, a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. The company is leveraging their atac platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. The company was founded by Nathaniel Brooks Horwitz and Jamie Kasuboski. The CEO is Daniel S. Grau. | Directeur/Membre du Conseil | 01/10/2020 |
Medical Microinstruments SpA
 Medical Microinstruments SpA Medical SpecialtiesHealth Technology Medical Microinstruments SpA develops and manufactures surgical micro-instruments. The firm focuses on clinical outcomes for patients undergoing microsurgery, and offers advanced microsurgical procedures, while reducing costs for patients, hospitals and for society at large. The company was founded by Giuseppe Prisco, Hannah Teichmann and Massimiliano Simi in 2015 and is headquartered in Calci, Italy. | Directeur/Membre du Conseil | 20/07/2022 |
Nodexus, Inc.
 Nodexus, Inc. Miscellaneous Commercial ServicesCommercial Services Nodexus, Inc. operates as a biotechnology services platform. It provides research and diagnostics, drug discovery, cell line development, forensics, CRISPR, and animal vaccination. The company was founded by Karthik Balakrishnan and Anand Kesavarajuin 2014 and is headquartered in Hayward, CA. | Directeur/Membre du Conseil | - |
| Research Alliance Holdings II LLC | Corporate Officer/Principal | - |
Anciens postes connus de Tess Cameron
| Sociétés | Poste | Fin |
|---|---|---|
| CYTEK BIOSCIENCES, INC. | Directeur/Membre du Conseil | 01/06/2022 |
| FOGHORN THERAPEUTICS INC. | Corporate Officer/Principal | 01/06/2020 |
| WAVE LIFE SCIENCES LTD. | Directeur/Membre du Conseil | 01/01/2018 |
| ░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Formation de Tess Cameron
| University of Toronto | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| WAVE LIFE SCIENCES LTD. | Health Technology |
| BIOGEN INC. | Health Technology |
| CYTEK BIOSCIENCES, INC. | Health Technology |
| FOGHORN THERAPEUTICS INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
RA Capital Management LP (Private Equity)
RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Finance |
Avilar Therapeutics, Inc.
Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avilar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of extracellular protein degraders. The company is based in an undisclosed location. The company has developed a proprietary discovery platform that includes novel, high-affinity, small molecule asgpr ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of atac mediated endocytosis and degradation. Avilar is developing atacs, a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. The company is leveraging their atac platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. The company was founded by Nathaniel Brooks Horwitz and Jamie Kasuboski. The CEO is Daniel S. Grau. | Commercial Services |
Medical Microinstruments SpA
Medical Microinstruments SpA Medical SpecialtiesHealth Technology Medical Microinstruments SpA develops and manufactures surgical micro-instruments. The firm focuses on clinical outcomes for patients undergoing microsurgery, and offers advanced microsurgical procedures, while reducing costs for patients, hospitals and for society at large. The company was founded by Giuseppe Prisco, Hannah Teichmann and Massimiliano Simi in 2015 and is headquartered in Calci, Italy. | Health Technology |
Nodexus, Inc.
Nodexus, Inc. Miscellaneous Commercial ServicesCommercial Services Nodexus, Inc. operates as a biotechnology services platform. It provides research and diagnostics, drug discovery, cell line development, forensics, CRISPR, and animal vaccination. The company was founded by Karthik Balakrishnan and Anand Kesavarajuin 2014 and is headquartered in Hayward, CA. | Commercial Services |
Research Alliance Corp. II
 Research Alliance Corp. II Financial ConglomeratesFinance Research Alliance Corp. II operates as a blank check company. The company was founded by Peter Kolchinsky, Matthew Hammond and Tess Cameron on July 17, 2020 and is headquartered in Las Vegas, NV. | Finance |
| Research Alliance Holdings II LLC |
